| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA |
| 09 Sep 2026 |
Form 4: Nicholson Nur, Chief Technology Officer
Granted 220,000 Stock Option (right to buy) |
| 09 Sep 2026 |
Form 3: Nicholson Nur, Chief Technology Officer
No securities owned |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 |
| 05 Aug 2026 | SCHEDULE 13G |
| 08 Jul 2026 |
Form 4: Tregoning Kathleen, See Remarks
Granted 175,000 Stock Option (right to buy) |
| 08 Jul 2026 |
Form 3: Tregoning Kathleen, See Remarks
No securities owned |
| 11 Jun 2026 |
Form 4: Renaud Ronald C Jr, Director
Received 38,094 shares by exercise or conversion ($200K) |
| 26 May 2026 | 10-Q |
| 26 May 2026 |
8-K: Results of Operations and Financial Condition
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline |
| 23 Apr 2026 | SCHEDULE 13D |
| 23 Apr 2026 | SCHEDULE 13D |
| 22 Apr 2026 |
Form 4: Rtw INVESTMENTS, Lp, 10% owner and 1 other
Received 10,276,820 shares by conversion · Bought 500,000 shares ($8M) |
| 22 Apr 2026 |
Form 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% owner
Received 11,511,852 shares by conversion |
| 20 Apr 2026 |
Form 4: Bain Capital Investors Llc, 10% owner and 4 others
Received 17,857,143 shares by conversion · Bought 8,398,438 shares ($134M) |
| 20 Apr 2026 |
Form 4: Koppel Adam, Director
Granted 38,300 Stock Option (right to buy) · Received 21,020,768 shares by conversion · Bought 1,562,500 shares ($25M) |
Loading...